Barclays Issues Pessimistic Forecast for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its price objective trimmed by Barclays from $10.00 to $6.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts also recently weighed in on the stock. UBS Group reduced their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. Citigroup reduced their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Finally, Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.86.

GoodRx Trading Down 2.1 %

Shares of GDRX opened at $4.56 on Monday. The stock has a market capitalization of $1.73 billion, a PE ratio of -152.00, a P/E/G ratio of 3.22 and a beta of 1.39. The company’s fifty day moving average is $6.62 and its 200 day moving average is $7.44. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx has a fifty-two week low of $4.55 and a fifty-two week high of $9.26.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

Institutional investors have recently made changes to their positions in the company. Beacon Capital Management LLC bought a new position in GoodRx during the 1st quarter worth about $28,000. nVerses Capital LLC purchased a new stake in shares of GoodRx in the 3rd quarter worth approximately $33,000. Plato Investment Management Ltd bought a new position in shares of GoodRx during the second quarter valued at approximately $43,000. Dark Forest Capital Management LP purchased a new position in GoodRx during the second quarter valued at approximately $86,000. Finally, EntryPoint Capital LLC raised its stake in GoodRx by 165.2% in the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock worth $132,000 after buying an additional 11,548 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.